Author details

Full Name

Qiang Yu

Affiliation

ORCID

Career Start Year

2001

Papers

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
36600243	Intimate communications within the tumor microenvironment: stromal factors function as an orchestra.		2023
37210576	EZH2 mediated metabolic rewiring promotes tumor growth independently of histone methyltransferase activity in ovarian cancer.	Mol Cancer	2023
36788227	Targeting PSAT1 to mitigate metastasis in tumors with p53-72Pro variant.	Signal Transduct Target Ther	2023
36627901	Cancer-associated fibroblasts as accomplices to confer therapeutic resistance in cancer.		2022
35840558	Hypoxia induces HIF1Î±-dependent epigenetic vulnerability in triple negative breast cancer to confer immune effector dysfunction and resistance to anti-PD-1 immunotherapy.	Nat Commun	2022
35878022	IFI16-dependent STING signaling is a crucial regulator of anti-HER2 immune response in HER2+ breast cancer.	Proc Natl Acad Sci U S A	2022
36201246	RAD21 amplification epigenetically suppresses interferon signaling to promote immune evasion in ovarian cancer.	Journal of Clinical Investigation	2022
34930899	Colorectal cancer-associated fibroblasts promote metastasis by up-regulating LRG1 through stromal IL-6/STAT3 signaling.	Cell Death and Disease	2021
34290255	Stromal induction of BRD4 phosphorylation Results in Chromatin Remodeling and BET inhibitor Resistance in Colorectal Cancer.	Nature Communications	2021
33402387	Targeting the IRAK1-S100A9 Axis Overcomes Resistance to Paclitaxel in Nasopharyngeal Carcinoma.	Cancer Res	2021
34464356	Targeting enhancer reprogramming to mitigate MEK inhibitor resistance in preclinical models of advanced ovarian cancer.	J Clin Invest	2021
34709752	Interleukin enhancer-binding factor 2 promotes cell proliferation and DNA damage response in metastatic melanoma.	Clin Transl Med	2021
34481935	CREBBP cooperates with the cell cycle machinery to attenuate chidamide sensitivity in relapsed/refractory diffuse large B-cell lymphoma.	Cancer Letters	2021
34881526	Inhibition of the PLK1-Coupled Cell Cycle Machinery Overcomes Resistance to Oxaliplatin in Colorectal Cancer.	Advanced Science	2021
33294586	Mesenchymal Stem Cell-Secreted Exosome Promotes Chemoresistance in Breast Cancer via Enhancing miR-21-5p-Mediated Expression.	Molecular Therapy - Oncolytics	2020
31896747	Gut stem cell aging is driven by mTORC1 via a p38 MAPK-p53 pathway.	Nature Communications	2020
33208750	EZH2-mediated PP2A inactivation confers resistance to HER2-targeted breast cancer therapy.	Nature Communications	2020
31061538	Methionine is a metabolic dependency of tumor-initiating cells.	Nature Medicine	2019
31135266	HER2-L755S mutation induces hyperactive MAPK and PI3K-mTOR signaling, leading to resistance to HER2 tyrosine kinase inhibitor treatment.	Cell Cycle	2019
31114058	Publisher Correction: Methionine is a metabolic dependency of tumor-initiating cells.	Nature Medicine	2019
29187402	The E3 Ligase RING1 Targets p53 for Degradation and Promotes Cancer Cell Proliferation and Survival.	Cancer Research	2018
29891662	Hypoxic tumor microenvironment activates GLI2 via HIF-1Î± and TGF-Î²2 to promote chemoresistance in colorectal cancer.	Proceedings of the National Academy of Sciences of the United States of America	2018
30266800	KDM4B-regulated unfolded protein response as a therapeutic vulnerability in -deficient breast cancer.	Journal of Experimental Medicine	2018
29925528	KDM6B Counteracts EZH2-Mediated Suppression of <i>IGFBP5</i> to Confer Resistance to PI3K/AKT Inhibitor Treatment in Breast Cancer.	Mol Cancer Ther	2018
30279971	Inhibition of interleukin-1 receptor-associated kinase 1 (IRAK1) as a therapeutic strategy.	Oncotarget	2018
28280357	A new tumor suppressor lncRNA RP11-190D6.2 inhibits the proliferation, migration, and invasion of epithelial ovarian cancer cells.	OncoTargets and Therapy	2017
28459468	Oncogenic KRAS-associated gene signature defines co-targeting of CDK4/6 and MEK as a viable therapeutic strategy in colorectal cancer.	Oncogene	2017
28381186	The expression pattern of long non-coding RNA PVT1 in tumor tissues and in extracellular vesicles of colorectal cancer correlates with cancer progression.	Tumor Biology	2017
28496335	Knockdown of a DIS3L2 promoter upstream long noncoding RNA (AC105461.1) enhances colorectal cancer stem cell properties in vitro by down-regulating DIS3L2.	OncoTargets and Therapy	2017
28893800	Deficiency Drives Enhancer Activation of Oncogenes in Clear Cell Renal Cell Carcinoma.	Cancer Discovery	2017
28846068	Pericyte-targeting prodrug overcomes tumor resistance to vascular disrupting agents.	Journal of Clinical Investigation	2017
28526299	MiR-200a Regulates CDK4/6 Inhibitor Effect by Targeting CDK6 in MetastaticÂ Melanoma.	J Invest Dermatol	2017
28967919	Chromosome 1q21.3 amplification is a trackable biomarker and actionable target for breast cancer recurrence.	Nat Med	2017
27459028	Molecular switch of EZH2 in hypoxia.	Cell Cycle	2016
27303043	HIFI-Î± activation underlies a functional switch in the paradoxical role of Ezh2/PRC2 in breast cancer.	Proceedings of the National Academy of Sciences of the United States of America	2016
27297789	EZH2 phosphorylation by JAK3 mediates a switch to noncanonical function in natural killer/T-cell lymphoma.	Blood	2016
26585835	Corrigendum: IRAK1 is a therapeutic target that drives breast cancer metastasis and resistance to paclitaxel.	Nat Commun	2015
25928216	Functional Characterization of D9, a Novel Deazaneplanocin A (DZNep) Analog, in Targeting Acute Myeloid Leukemia (AML).	PLoS ONE	2015
25328122	Elevated expression of long intergenic non-coding RNA HOTAIR in a basal-like variant of MCF-7 breast cancer cells.	Molecular Carcinogenesis	2015
25319940	3-Deazaneplanocin A and neplanocin A analogues and their effects on apoptotic cell death.	ChemMedChem	2015
26116990	Preclinical pharmacokinetic studies of 3-deazaneplanocin A, a potent epigenetic anticancer agent, and its human pharmacokinetic prediction using GastroPlusâ¿¢.	European Journal of Pharmaceutical Sciences	2015
25225797	The KDM2B- let-7b -EZH2 axis in myelodysplastic syndromes as a target for combined epigenetic therapy.	PLoS ONE	2014
25384218	RASAL2 activates RAC1 to promote triple-negative breast cancer progression.	J Clin Invest	2014
24213577	The Polycomb group (PcG) protein EZH2 supports the survival of PAX3-FOXO1 alveolar rhabdomyosarcoma by repressing FBXO32 (Atrogin1/MAFbx).	Oncogene	2014
24226421	Tumor necrosis factor-Î± and apoptosis induction in melanoma cells through histone modification by 3-deazaneplanocin A.	J Invest Dermatol	2014
23542171	CTSL2 is a pro-apoptotic target of E2F1 and a modulator of histone deacetylase inhibitor and DNA damage-induced apoptosis.	Oncogene	2014
24953652	EZH2-mediated inactivation of IFN-Î³-JAK-STAT1 signaling is an effective therapeutic target in MYC-driven prostate cancer.	Cell Reports	2014
25032847	Integrative epigenome analysis identifies a Polycomb-targeted differentiation program as a tumor-suppressor event epigenetically inactivated in colorectal cancer.	Cell Death and Disease	2014
25008978	Nanoscale chromatin profiling of gastric adenocarcinoma reveals cancer-associated cryptic promoters and somatically acquired regulatory elements.	Nature Communications	2014
23668928	Molecular mechanisms of tumor resistance to PI3K-mTOR-targeted therapy.	Chinese Journal of Cancer	2013